Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
October 25, 2018 07:30 ET
|
Spark Therapeutics, Inc.
The Eye Want 2 Know digital resource helps patients and their families in the U.S. living with an inherited retinal disease (IRD) learn about genetic testing and includes a “Find A Provider” tool to...
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
October 08, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Annuncia il Parere positivo del CHMP per la Terapia Genica una tantum LUXTURNA® (voretigene neparvovec) nell’Unione europea
September 25, 2018 12:49 ET
|
Spark Therapeutics, Inc.
LUXTURNA diventerebbe la prima terapia genica per una malattia genetica approvata sia negli USA sia nella UE LUXTURNA sarebbe la prima e unica terapia genica approvata nell’UE per il trattamento di...
Spark Therapeutics gibt zustimmende Bewertung des Ausschusses für Humanarzneimittel für die einmalig verabreichte Gentherapie LUXTURNA® (Voretigen Neparvovec) in der Europäischen Union bekannt
September 25, 2018 12:49 ET
|
Spark Therapeutics, Inc.
LUXTURNA wäre die erste Gentherapie für eine genetische Erkrankung, die sowohl in den USA als auch in der EU zugelassen ist LUXTURNA wäre die erste und einzige...
Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
September 21, 2018 07:17 ET
|
Spark Therapeutics, Inc.
LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to...
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
August 07, 2018 07:30 ET
|
Spark Therapeutics, Inc.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show: A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized...
Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias „besten Arbeitgeber“ ausgezeichnet
August 03, 2018 15:23 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
August 03, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics veranstaltet am Dienstag, 7. August, um 8.30 Uhr ET (Ostküstenzeit) eine Telefonkonferenz, um über die Unternehmens- und Finanzergebnisse des zweiten Quartals und die neuesten Geschäftserfolge zu sprechen
July 31, 2018 14:16 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
July 31, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...